SCHEMBL4672955

SCHEMBL4672955

O=C(Cc1ccc(Cc2cccc(Cl)c2)o1)C(=O)c1nc[nH]n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.43
LMNA P02545 2/20 0.37
PTGER1 P34995 1/20 0.37
ALDH1A1 P00352 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
MAPT P10636 1/20 0.35
HTT P42858 1/20 0.35
PIK3CA P42336 1/20 0.35
TAAR1 Q96RJ0 1/20 0.35
CTBP2 P56545 1/20 0.34
MEN1 O00255 1/20 0.34
HPGD P15428 1/20 0.34
KMT2A Q03164 1/20 0.34
RXRA P19793 1/20 0.34
RXRB P28702 1/20 0.34
RXRG P48443 1/20 0.34
HDAC3 O15379 1/20 0.34
HDAC1 Q13547 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4671810 0.88 HCAR2 (0.42) HCAR2LMNAALDH1A1MAPTTAAR1
SCHEMBL4678966 0.87 PTGER1 (0.35) HCAR2PTGER1HDAC1
SCHEMBL4678602 0.86 SMN1; SMN2 (0.38) LMNAPTGER1ALDH1A1SMN1; SMN2MAPT
SCHEMBL4673041 0.86 HCAR2 (0.38) HCAR2LMNAALDH1A1SMN1; SMN2PDE3B
SCHEMBL4671287 0.86 NR3C2 (0.40) ALDH1A1SMN1; SMN2HTTCTBP2
SCHEMBL4677064 0.85 NR3C2 (0.39) LMNASMN1; SMN2MAPTHTTMEN1
SCHEMBL4679970 0.85 HCAR2 (0.39) HCAR2LMNAALDH1A1SMN1; SMN2PDE3B
SCHEMBL4676484 0.83 KDM5A (0.35) PTGER1MAPTHTTMAOAMAOB
SCHEMBL4672377 0.83 HCAR2 (0.39) HCAR2LMNAPTGER1PDE3BPDE3A
SCHEMBL4672900 0.82 HTT (0.33) PTGER1ALDH1A1SMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 HCAR2 276/4885LMNA 659/4885PTGER1 4379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.